Bal Pharma, registered a revenue growth of 36 per cent at Rs. 70.96 crore as compared to the corresponding quarter of last year at Rs. 52.2 8 crore. EBITDA grew by 46 per cent at Rs. 7.62 crore as against Rs. 5.24 crore in the last Q1 FY 2021. PAT is at Rs. 1.65 crore registering 47.1 per cent over last year’s Q1 at Rs 0.28 crore.
Bal Pharma, registered a revenue growth of 36 per cent at Rs. 70.96 crore as compared to the corresponding quarter of last year at Rs. 52.2 8 crore. EBITDA grew by 46 per cent at Rs. 7.62 crore as against Rs. 5.24 crore in the last Q1 FY 2021. PAT is at Rs. 1.65 crore registering 47.1 per cent over last year’s Q1 at Rs 0.28 crore.
Bal Pharma Limited (Bal Pharma), the largest Indian pharmaceutical producer of the bulk drug Gliclazide, an oral hypoglycemic (anti-diabetic drug) claimed victory for the recent imposition of Anti-Dumping Duty imposed by the Indian Ministry of Finance on imports of the bulk substance from China. According to a filing with the Bombay Stock Exchange, Bal Pharma, with manufacturing facilities located in Bangalore, Pune and Uttaranchal, manufactures Gliclazide at its Bangalore facility for both domestic and certain overseas markets.
Bal Pharma eyes novel extraction tech process, inks an EDA with US-based Plandai to market Phytofare in India
Bal Pharma gains after launching OTC medicine in Bangalore
Bal Pharma Ltd launches OTC product `Eye Spa` in Bangalore